References
- 1988 Joint National Committee. “The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure,”. Arch. Intern. Med. 1988; 148: 1023
- Ajayi A. A., Elliott H. L., Reid J. L. “The Pharmacodynamics and Dose-Response Relationships of the Angiotensin Converting Enzyme Inhibitor Cilazapril in Essential Hypertension,”. Br. J. Clin. Pharmacol 1986; 22: 167
- Holck M., Fischli W., Hefti F., Gerold M. “Cardiovascular Effects of the New Angiotensin-Converting-Enzyme Inhibitor, Cilazapril, in Anesthetized and Conscious Dogs,”. J. Cardiovasc. Pharmacol. 1986; 8: 99
- Tanaka H., Yoneyama Y., Sugawara M., Umeda I., Ohta Y. “Enzyme Immunoassay Discrimination of a New Angiotensin-Converting Enzyme (ACE) Inhibitor, Cilazapril, and Its Active Metabolite,”. J. Pharm. Sci. 1987; 76: 224
- Natoff I. L., Nixon J. S., Francis R. J., et al. “Biological Properties of the Angiotensin-Converting Enzyme Inhibitor Cilazapril,”. J. Cardiovasc. Pharmacol. 1985; 7: 569
- Fasanella d'Amore T., Bussien J. P., Nussberger J., et al. “Effects of Single Doses of the Converting Enzyme Inhibitor Cilazapril in Normal Volunteers,”. J. Cardiovasc. Pharmacol. 1987; 9: 26